source
- Theravance, after clinical setbacks, agrees to $929M buyoutThe acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
- 5 takeaways from STAT’s investigation into microhospital operator Nutex HealthRead the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.